A Meta-Analysis of the Utility of C-Reactive Protein, Erythrocyte Sedimentation Rate, Fecal Calprotectin, and Fecal Lactoferrin to Exclude Inflammatory Bowel Disease in Adults With IBS

Menees, Stacy B.; Powell, Corey; Kurlander, Jacob E.; Goel, Akash; Chey, William D.

doi:10.1038/ajg.2015.6

Cited by 315 publications

(229 citation statements)

References 48 publications

Supporting

Mentioning

176

Contrasting

Unclassified

Order By: Relevance

“…IBS, IBD, and healthy controls. Careful analysis of Menees et al's study 71 (Figs. 2-5) shows that the predictive probability of being a healthy control or having IBS at different levels do not have a real overlap at least numerically, suggesting that there might be a difference between IBS and healthy controls based on these biomarkers.…”

Section: Biomarkers Of Inflammationmentioning

confidence: 99%

See 1 more Smart Citation

Immune activation in irritable bowel syndrome: from basic to clinic

Bashashati¹

2022

NGL

View full text Add to dashboard Cite

RESUMENEl síndrome de intestino irritable (SII) es un trastorno funcional intestinal común con una etiología no identificada. La activación de bajo grado del sistema autoinmunitario ha sido considerada la fisiopatología de este trastorno. En los pacientes que lo padecen, las concentraciones de citocinas están alteradas y las células inmunitarias se infiltran en el intestino. Además, en los pacientes con SII se ha observado la activación de estas células inmunitarias y la presencia de alergias alimenticias. Sin embargo, las características del perfil inmunológico de los pacientes con SII pueden ser objeto de debate en la práctica clínica, dado que no existen criterios bien establecidos para diferenciar el SII en controles sanitarios basados en estos parámetros. Esta revisión plantea el rol del sistema inmunitario en la fisiopatología del SII y explora los potenciales roles de estos biomarcadores durante el tratamiento clínico de estos pacientes.

show abstract

Section: Biomarkers Of Inflammationmentioning

confidence: 99%

“…The overproduction of proteins involved in the aggregation of red blood cells increases ESR. Two other markers of intestinal inflammation are lactoferrin and calprotectin which are secreted by activated neutrophils into the feces 71 .…”

Section: Biomarkers Of Inflammationmentioning

confidence: 99%

Immune activation in irritable bowel syndrome: from basic to clinic

Bashashati¹

2022

NGL

View full text Add to dashboard Cite

show abstract

“…When screening donors, we believe fecal calprotectin should be included into the laboratory testing panel with a cutoff of 40 mg/g for it is associated with 1% probability of having occult IBD. 7 Notably, in the case of universal donors when multiple recipients will be exposed, it is particularly important. Moreover, when banking universal donor material, consideration should be given to quarantining before usage -as practiced by stool banks -to allow for identification of latent disease and to increase the safety of FMT.…”

Section: To the Editormentioning

confidence: 99%

Can you cause inflammatory bowel disease with fecal transplantation? A 31-patient case-series of fecal transplantation using stool from a donor who later developed Crohn's disease

et al. 2017

View full text Add to dashboard Cite

“…Valuable information was provided by a meta-analysis, although that assessed their cut-off values in order to exclude inflammatory bowel diseases [74].…”

Section: Low-grade Inflammationmentioning

confidence: 99%

Inflammation as a Potential Therapeutic Target in IBS

Chira¹,

Chira²,

Dumitraşcu³

2016

Irritable Bowel Syndrome - Novel Concepts for Research and Treatment

View full text Add to dashboard Cite

The pathogenesis of irritable bowel syndrome (IBS) has been intensively researched, and despite a long journey for unraveling all the structures and the pathways involved, it still remains partially obscure. Inflammation was the first to be hypothesized as a potential pathway for the pathogenesis of IBS. It remains a keystone in the complex machinery of the pathogenesis that is currently considered multifactorial. Elucidating the pathogenesis of IBS is crucial for a targeted therapy of the disease. In this chapter, we review information regarding gut inflammation in IBS, underlining some of the newest data or the cornerstones. Additionally, our aim was also to review treatment currently available and future perspectives regarding anti-inflammatory treatments for IBS. Newer techniques allow detection and research of mediators involved in inflammation, as well as their potential role to be targeted by pharmacological agents. Recent data supports not only further research of the newer agents that are currently being developed but also some of the available ones that do not have sufficient evidence. Emerging therapies that target inflammation are under evaluation, in trials. A multidrug or a multidisciplinary approach needs to be considered in some cases that fail to respond to current treatment.

show abstract

A Meta-Analysis of the Utility of C-Reactive Protein, Erythrocyte Sedimentation Rate, Fecal Calprotectin, and Fecal Lactoferrin to Exclude Inflammatory Bowel Disease in Adults With IBS

Abstract: CRP and calprotectin of ≤0.5 or 40, respectively, essentially excludes IBD in patients with IBS symptoms. The addition of CRP and calprotectin to symptom-based criteria may improve the confident diagnosis of IBS.

Cited by 315 publications

References 48 publications

Immune activation in irritable bowel syndrome: from basic to clinic

Immune activation in irritable bowel syndrome: from basic to clinic

Can you cause inflammatory bowel disease with fecal transplantation? A 31-patient case-series of fecal transplantation using stool from a donor who later developed Crohn's disease

Inflammation as a Potential Therapeutic Target in IBS

Contact Info

Product

Resources

About